Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Sildenafil (Primary)
- Indications Chronic heart failure; Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 24 Nov 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 24 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated